Pfizer's financial results haven't been great in the past couple of years, as its pandemic-related products are no longer the growth drivers they once were. The company will also encounter some ...
Since 2012, Vertex has been the only drugmaker with treatments that address the root cause of cystic fibrosis. Vertex Pharmaceuticals recently received FDA approval for a gene therapy developed in ...
- Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex ...
Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex ...
Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs. 10 stocks we like better than ...
Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results